In situ assessment of effects of the bromide- and fluoride-incorporating adhesive systems on biofilm and secondary caries.

AIM: This in situ study assessed the effects of adhesive systems containing or not fluoride and/or the antibacterial monomer 12-methacryloyloxydodecylpyridinium bromide (MDPB) on the microbiological composition of dental biofilm and enamel demineralization. MATERIALS AND METHODS: During two phases of 14 days, ten volunteers wore intraoral palatal appliances containing two slabs of human enamel according to a double-blind, crossover design. The slabs were randomly restored using a composite resin and one of the following adhesive systems: All-Bond SE(TM) (self-etch, fluoride/MDPB free adhesive, AB) and Clearfl Protect Bond (self-etch containing fluoride and MDPB adhesive, CB). The biofilm formed on the slabs was analyzed with regard to total and mutans streptococci and lactobacilli counts. Demineralization represented by integrated area of hardness × lesion depth Delta S ( ΔS) was determined on enamel by analysis of cross-sectional microhardness, at 20 and 70 µm from the restoration margin. Data were analyzed by ANOVA. RESULTS: No statistically significant difference was found either in enamel demineralization or in the microbiological composition of dental biofilm. CONCLUSION: All adhesive systems containing or not fluoride and/or MDPB tested were unable to inhibit secondary caries in the in situ model used in the present research.

Asoxime (HI-6) impact on dogs after one and tenfold therapeutic doses: assessment of adverse effects, distribution, and oxidative stress.

Asoxime (HI-6) is a well known oxime reactivator used for counteracting intoxication by nerve agents. It is able to reactivate acetylcholinesterase (AChE) inhibited even by sarin or soman. The present experiment was aimed to determine markers of oxidative stress represented by thiobarbituric acid reactive substances and antioxidants represented by ferric reducing antioxidant power, reduced and oxidized glutathione in a Beagle dog model. Two groups of dogs were intramuscularly exposed to single (11.4 mg/kg.b.wt.) or tenfold (114 mg/kg.b.wt.) human therapeutically doses of HI-6. HI-6 affinity for AChE in vitro was evaluated in a separate experiment. Complete serum biochemistry and pharmacokinetics were also performed with significant alteration in blood urea nitrogen, creatine phosphokinase, glucose and triglycerides. Blood samples were collected before HI-6 application and after 30, 60, and 120 min. The overall HI-6 impact on organism is discussed.

Assessment of the therapeutic and anticonvulsive efficacy of a drug combination consisting of trihexyphenidyle and HI-6 in soman-poisoned rats.

1. The influence of two anticholinergic drugs (atropine, trihexyphenidyle) on the effectiveness of antidotal treatment to eliminate soman-induced lethal effects and convulsions was studied in rats. 2. The oxime HI-6 when combined with centrally acting anticholinergic drug trihexyphenidyle seems to be more efficacious in the elimination of acute toxic effects of soman than its combination with atropine. 3. The findings support the hypothesis that the choice of the anticholinergic drug is important for the effectiveness of antidotal mixture in the case of antidotal treatment of soman-induced acute poisoning.

Quantitative assessment of placental transfer of fazadinium in obstetric anaesthesia.

Fazadinium, 1 mg/kg, was administered to 16 women undergoing general anaesthesia for casearean section or vaginal delivery with forceps. Fazadinium serum levels were measured fluorimetrically in samples of maternal venous blood and umbilical arterial and venous blood obtained at the time of delivery. The umbilical to maternal ratio of venous fazadinium averaged 20% and was not influenced by the interval between induction and delivery. A lower concentration was found in the umbilical artery, and the arterial to venous cord blood concentration ratio was about 75% suggesting foetal drug uptake. In all cases, Apgar scores were normal at the fifth minute. It is concluded that there is a placental transfer of fazadinium; however, this transfer is limited and the risk of paralysis of the newborn appears unlikely after a single intubating dose of 1 mg/kg administered to the mother.